Over the years, immunostimulating gene therapies have been evaluated extensively in animal models in which robust Th1-mediated immunity that often was dependent on CD8+ T lymphocytes was induced and the cured mice were protected against subsequent tumor challenge [9,10,11,12,13,14,26,27,28,29,30,31,32]. Here, CD8A is linked to neoplasm.